Compare MPLX LP (MPLX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs BIO-TECHNE Corp — how do they compare? MPLX LP trades at $59.3 (market cap $59.51B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: MPLX LP is far larger — about 5.3× BIO-TECHNE Corp's market cap, and MPLX LP pays the higher dividend (7.34%). Which is the better fit depends on your goals.
| MPLX | TECH | |
|---|---|---|
Market Cap | $59.51B | $11.24B |
Sector | Technology | Health |
52-Week High | $60.51 | $72.29 |
52-Week Low | $47.80 | $43.31 |
Enterprise Value | $84.62B | $11.32B |
Dividend Yield | 7.34% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $58.85, down 2.6% today, with a bullish technical outlook supported by moving averages and strong institutional support. The company maintains robust profitability with 40.45% net income margin and 33.95% ROE, though recent quarters showed mixed earnings performance with two misses. Recent news highlights MPLX's $2.25 billion senior notes offering and solid Q2 2026 results with 5% EBITDA growth.
The stock presents a compelling income opportunity with a 7.3% yield and analyst consensus price target of $61.50 (4.5% upside). Key risks include execution challenges from higher capital spending and leverage concerns, while growth projects in natural gas and NGL services provide multi-year visibility.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
